Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Other Accumulated Expenses for 8 consecutive years, with $24.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 73.27% year-over-year to $24.4 million; the TTM figure through Mar 2026 stood at $24.4 million (up 73.27% YoY), while the FY2025 annual figure was $21.4 million, up 9474.44% from the prior year.
• Other Accumulated Expenses grew to $24.4 million in Q1 2026 per KYMR's latest filing, from $21.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $24.4 million in Q1 2026 and bottomed at $117000.0 in Q2 2025.
• Historically, Other Accumulated Expenses has averaged $5.9 million across 5 years, with a median of $824000.0 in 2024.
• On a YoY basis, Other Accumulated Expenses climbed as much as 89727.78% in 2022 and fell as far as 97.32% in 2022.
• Kymera Therapeutics' Other Accumulated Expenses stood at $407000.0 in 2022, then climbed by 28.75% to $524000.0 in 2023, then plunged by 57.44% to $223000.0 in 2024, then jumped by 9474.44% to $21.4 million in 2025, then advanced by 14.16% to $24.4 million in 2026.
• Business Quant data shows KYMR's Other Accumulated Expenses at $24.4 million in Q1 2026, $21.4 million in Q4 2025, and $267000.0 in Q3 2025.